Comparison of next-morning residual effects by bedtime administration of vornorexant and zopiclone in healthy older participants: postural stability, neuropsychological functions, and subjective sleepiness in a randomized clinical study

Abstract Rationale Vornorexant is a novel dual orexin receptor antagonist for insomnia treatment with the shortest half-life in its class. Objective This study aimed to compare the next-morning residual effects of vornorexant and zopiclone following bedtime administration in healthy older adults. Methods In this randomized, double-blind, placebo- and active-controlled, four-way crossover study, 16 healthy participants aged ≥65 years received single bedtime doses of vornorexant (5 and 10 mg), pla